RARA CRAFT DATABASE for FDA Medical Devices
510(k)K173969

FDA DEVICE FACTS

Medicalgorithmics Unified Cardiac Rehabilitation System

Medicalgorithmics S.A.

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATEJuly 11, 2018PRODUCT CODEDSI

Indications for use

Complete original indications for use

PocketECG CRS is intended to be used for: 1. Cardiac monitoring of patients undergoing a cardiac rehabilitation program. Its main feature is patient monitoring during previously planned training sessions and training assistance to achieve desired intensity and duration of workout. Training session parameters such as heart rate threshold, session duration (time intervals and number of repetitions) are defined by the physician for each patient individually. Additionally, the transmitter allows continuous ECG monitoring between trainings, during patient daily activities. 2. All patients hospitalized with a primary diagnosis of an acute myocardial infarction (MI) or chronic stable angina (CSA), or who during hospitalization have undergone coronary artery bypass graft (CABG) surgery, a percutaneous coronary intervention (PCI), cardiac valve surgery, or cardiac transplantation, referred to an early outpatient cardiac rehabilitation or secondary prevention (CR) program. 3. All patients evaluated in an outpatient setting who within the past 12 months have experienced an acute myocardial infarction (MI), coronary artery bypass graft (CABG) surgery, a percutaneous coronary intervention (PCI), cardiac valve surgery, or cardiac transplantation, or who have chronic stable angina (CSA) and have not already participated in an early outpatient cardiac rehabilitation or secondary prevention (CR) program for the qualifying event or diagnosis, referred to such a program. 4. Patients who require monitoring for: a) non-life threatening arrhythmias such as supraventricular tachycardias (e.g. atrial fibrillation, atrial flutter, PACs, PSVT) and ventricular ectopy; b) evaluation of bradyarrhythmias and intermittent bundle branch block, including after cardiovascular surgery and myocardial infarction; and c) arrhythmias associated with co-morbid conditions such as hyperthyroidism or chronic lung disease; 5. PocketECG CRS can be used to monitor the training session in hospital, rehabilitation center or physicians office under supervision of qualified staff.

Complete original IFU contraindications continuation

Contraindications: 1. Patients with recent change in the resting ECG suggesting significant ischemia, recent MI, or other acute cardiac event, 2. Patients with: unstable angina, symptomatic severe aortic stenosis or other valvular disease, decompensated symptomatic heart failure, acute pulmonary embolus or pulmonary infarction, acute myocarditis or pericarditis, or acute thrombophlebitis 3. Patients with potentially life-threatening arrhythmias who require inpatient monitoring, 4. Patients with physical disability that would preclude safe and adequate exercise performance, or with acute noncardiac disorder that may affect exercise performance or may be aggravated by exercise (e.g., infec¬tion, thyrotoxicosis), 5. The PocketECG CRS is not intended for use in surgical rooms, intensive care units, and emergency vehicles. The transmitter is MR unsafe and should not be used in any magnetic resonance environment.

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: August 27, 2026